ProPhase Labs Announces Preliminary Positive Results for Dietary Supplement Equivir
14 févr. 2024 08h00 HE
|
ProPhase Labs, Inc.
Commercialization of Equivir anticipated after second trial is completed in Q2, 2024 Garden City, NY, Feb. 14, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), a next generation...
ProPhase Labs Ushers in New Genomics Era with Jason Karkus at the Helm of Nebula Genomics
30 janv. 2024 08h00 HE
|
ProPhase Labs, Inc.
Garden City, NY, Jan. 30, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase” or the “Company”), a next generation biotech, genomics, therapeutics and diagnostics company,...
Pharmaloz Manufacturing Accelerates Expansion, Improves Pricing, Boosts Profitability and Secures New Contracts
23 janv. 2024 08h00 HE
|
ProPhase Labs, Inc.
Pharmaloz Wins Two New Contracts in January that are Anticipated to Significantly Increase Lozenge Revenues and ProfitabilityCompany in Late-Stage Discussions with Two Additional Large Global Brands...
ProPhase poised to ramp up growth at Pharmaloz and Nebula Genomics in 2024
04 janv. 2024 08h00 HE
|
ProPhase Labs, Inc.
Company also plans to commercialize its BE-Smart Esophageal Cancer Test in 2024Company announces the hiring of long-time industry veteran Jed Latkin as COO to help build and manage this growth Garden...
ProPhase Labs Announces Financial Results for the Three Months Ended September 30, 2023
09 nov. 2023 08h00 HE
|
ProPhase Labs, Inc.
Company sees significant momentum in Pharmaloz, Nebula Genomics and ProPhase BioPharma Pharmaloz Manufacturing plans on track to increase capacity from $10 million to over $75 million in 2024...
ProPhase Labs to Host Third Quarter 2023 Financial Results Conference Call on Thursday, November 9, 2023 at 11:00 a.m. Eastern Time
02 nov. 2023 08h00 HE
|
ProPhase Labs, Inc.
GARDEN CITY, NY, Nov. 02, 2023 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), a next generation biotech, genomics, therapeutics and diagnostics company, will hold a conference call on...
ProPhase Labs Announces Substantial Growth Expectations for Pharmaloz Manufacturing Subsidiary due to Skyrocketing Demand for Pharmaloz Output.
17 oct. 2023 08h00 HE
|
ProPhase Labs, Inc.
Pharmaloz plan is to build capacity with a goal to attain a revenue run-rate of $60 to $80 million by year-end 2024, with 20-25% pre-tax net margins and a goal for additional growth thereafter. ...
ProPhase Labs to Present at The ThinkEquity Conference
12 oct. 2023 08h00 HE
|
ProPhase Labs, Inc.
GARDEN CITY, NY, Oct. 12, 2023 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), a next generation biotech, genomics, therapeutics and diagnostics company, today announced it will be...
ProPhase Labs Announces Updated Conference Call Dial-in Information for Thursday August 10, 2023 at 11:00 a.m. Eastern Time for Second Quarter 2023 Financial Results Call.
10 août 2023 10h40 HE
|
ProPhase Labs, Inc.
Garden City, NY, Aug. 10, 2023 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) Conference Call and Webcast Details Management will host a conference call at 11:00 AM ET, Thursday, August...
ProPhase Labs Announces Financial Results for the Three Months Ended June 30, 2023
10 août 2023 08h00 HE
|
ProPhase Labs, Inc.
Company believes that the combined value of its five operating units exceeds its current market capitalization and that each unit has significant growth potential. Company highlights...